Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure

American Journal of Ophthalmology
John H K LiuRobert N Weinreb

Abstract

To compare the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure (IOP) in patients with ocular hypertension or early glaucomatous changes. Prospective, open-label, experimental study with crossover design. Eighteen patients with ocular hypertension or early glaucomatous changes (aged 41 to 79 years) each received topical treatments with timolol (0.5% Timoptic-XE), latanoprost (0.005% Xalatan), and no IOP-lowering medication, for at least 4 weeks. Timolol was given once in the morning upon awakening and latanoprost once in the evening at bedtime. At the end of each treatment period, the patient was housed in a sleep laboratory for 24 hours and IOP was measured every 2 hours using a pneumatonometer. Measurements were taken sitting and supine during the 16-hour diurnal/wake period and only supine during the 8-hour nocturnal/sleep period. Mean diurnal and nocturnal IOP levels were compared among the treatments with timolol, latanoprost, and no medication. In the diurnal period, the mean IOP under the timolol or the latanoprost treatment was significantly less than the mean IOP under no medication in both the sitting and the supine positions. There was no statistical difference between the timolol and l...Continue Reading

References

Nov 1, 1978·Archives of Ophthalmology·R L Coakes, R F Brubaker
Aug 1, 1978·Experimental Eye Research·M E YablonskiB Becker
Apr 1, 1975·American Journal of Ophthalmology·Y Kitazawa, T Horie
Sep 1, 1989·Experimental Eye Research·B T Gabelt, P L Kaufman
Feb 1, 1997·Archives of Ophthalmology·A G KonstasW C Stewart
Nov 7, 1999·Acta Ophthalmologica Scandinavica·S KragT Sørensen
Sep 27, 2000·American Journal of Ophthalmology·W E SponselT Friberg
Sep 3, 2002·Survey of Ophthalmology·Birgitta Sjöquist, Johan Stjernschantz
Sep 3, 2002·Survey of Ophthalmology·Robert N WeinrebPaul L Kaufman
Sep 3, 2002·Survey of Ophthalmology·Lill-Inger LarssonLuca Rossetti
Oct 9, 2002·Archives of Ophthalmology·Anders HeijlUNKNOWN Early Manifest Glaucoma Trial Group
Mar 27, 2003·Investigative Ophthalmology & Visual Science·John H K LiuRobert N Weinreb
Oct 1, 1993·Journal of Glaucoma·J LaurenceT J Zimmerman

❮ Previous
Next ❯

Citations

Jun 16, 2012·Nature Reviews. Drug Discovery·Kang ZhangRobert N Weinreb
Oct 26, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Lieh Bin OngPillai Balaravi
Jan 7, 2010·Journal of Glaucoma·Michael D TwaRobert H Small
Dec 20, 2005·The British Journal of Ophthalmology·P FogagnoloN Orzalesi
Nov 30, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Sachie TanakaHiroshi Ohguro
Jun 3, 2014·Indian Journal of Ophthalmology·Harsha L RaoChandra S Garudadri
Dec 1, 2014·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Arthur J Sit
Nov 19, 2013·Investigative Ophthalmology & Visual Science·Cherie B NauArthur J Sit
Mar 1, 2011·Expert Opinion on Emerging Drugs·Anne J Lee, Ivan Goldberg
Dec 14, 2011·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Delan JinapriyaYvonne M Buys
Dec 12, 2012·Survey of Ophthalmology·Luciano QuarantaIvano Riva
Aug 12, 2009·Survey of Ophthalmology·Marla B SultanPaul P Lee
Dec 17, 2008·Survey of Ophthalmology·Arthur J Sit, Sanjay Asrani
Dec 17, 2008·Survey of Ophthalmology·Rania TabetAnastasios G P Konstas
Jun 10, 2008·Ophthalmology·Martin KabackUNKNOWN Brinzolamide 1%/Timolol 0.5% Study Group
Jul 15, 2015·Clinical & Experimental Ophthalmology·Kaweh MansouriRobert N Weinreb
Dec 8, 2015·Clinical & Experimental Ophthalmology·Jonathan S Myers, Scott J Fudemberg
Aug 14, 2013·British Journal of Pharmacology·A Guzman-AranguezJ Pintor
Feb 26, 2016·Advances in Therapy·Anastasios G P KonstasStefano Miglior
Mar 29, 2016·Survey of Ophthalmology·C Gustavo de MoraesRobert N Weinreb
Jul 22, 2009·American Journal of Ophthalmology·L Jay Katz, Jonathan S Myers
Sep 14, 2006·Current Medical Research and Opinion·J García-FeijooJ García-Sánchez
Nov 27, 2007·Expert Opinion on Pharmacotherapy·Jess T Whitson
May 24, 2013·Seminars in Ophthalmology·Kaweh MansouriFelipe A Medeiros
Jul 28, 2016·American Journal of Ophthalmology·John H K LiuRobert N Weinreb
Jan 28, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Leonard K SeiboldMalik Y Kahook
Jan 2, 2014·Therapeutic Advances in Chronic Disease·Deepak Sambhara, Ahmad A Aref
Jan 26, 2017·Current Eye Research·Shunsuke TsuchiyaKazuhisa Sugiyama
Apr 3, 2018·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Katsuhiro Ohyama, Munetoshi Sugiura
Sep 8, 2018·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Leonard K SeiboldMalik Y Kahook

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.